Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $290.28 million
P/E Ratio 11.80
Dividend Yield 3.44%
Shares Outstanding 389.63 million
Earnings per share 0.064
Dividend per share 0.05
Year To Date Return 2.72%
Earnings Yield 8.48%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Monash IVF Group Ltd (ASX: MVF)
    Latest News

    a business man in a suit holds his hand over his eyes as he bows his head in a defeated post suggesting regret and remorse.
    Share Fallers

    Why Brightstar, EVT, Monash IVF, and Pro Medicus shares are dropping today

    These shares aren't spreading the Christmas cheer on Wednesday.

    Read more »

    Shot of a senior scientist looking stressed out while working in a lab.
    Healthcare Shares

    After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

    Here’s what analysts at Macquarie rate the stock as now.

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why Collins Foods, Monash IVF, Premier Investments, and Step One shares are tumbling today

    These shares are ending the week in the red. But why?

    Read more »

    A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
    Broker Notes

    Analysts rate CBA and these popular ASX shares as sells

    Let's see why analysts are bearish on these names.

    Read more »

    Excited couple celebrating success while looking at smartphone.
    Share Gainers

    Why Gentrack, Monash IVF, Pro Medicus, and Qube shares are racing higher today

    These shares are having a strong start to the week. But why?

    Read more »

    Female scientist working in a laboratory.
    Healthcare Shares

    This Aussie fertility company has rejected a takeover bid from private equity

    Monash IVF has rejected a takeover offer from private equity, saying the bid significantly undervalues the IVF company.

    Read more »

    Doctor performing an ultrasound on pregnant woman
    Broker Notes

    Macquarie tips 54% upside for this beaten down ASX All Ords healthcare stock

    Turnaround time?

    Read more »

    Female scientist working in a laboratory.
    Healthcare Shares

    Monash IVF has named a new Managing Director to help right the ship

    Monash IVF has named a new leader, but she will not start in the top job for some time.

    Read more »

    A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
    Healthcare Shares

    Macquarie tips 46% upside for this ASX All Ords healthcare stock

    After a year dominated by bad news, the Macquarie team says it's time to buy this company's downtrodden shares.

    Read more »

    A woman is very excited about something she's just seen on her computer, clenching her fists and smiling broadly.
    Broker Notes

    Expert tips more than 50% upside for this ASX All Ords healthcare stock

    Those aiming for big returns should read on.

    Read more »

    Rising share price chart.
    Small Cap Shares

    These small cap ASX shares could rise 10% to 40%

    Analysts think these shares good generate big returns for investors.

    Read more »

    A smiling woman sits in front of her laptop with her baby in her lap looking at her rising ASX shares including the VAS ETF
    Healthcare Shares

    Does Macquarie rate Monash IVF shares a buy, hold, or sell post-results?

    Monash IVF shares got smashed on results day last week, so Macquarie's new rating may surprise you.

    Read more »

    Frequently Asked Questions

    Yes, Monash IVF Group has historically paid two fully franked shareholder dividends a year.

    Monash IVF Group generally pays its shareholder dividends in April and October. 

    Monash IVF Group listed on the ASX on 26 June 2014.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    06 Mar 2025 $0.0260 100.00% Interim 11 Apr 2025
    05 Sep 2024 $0.0250 100.00% Final 11 Oct 2024
    07 Mar 2024 $0.0250 100.00% Interim 05 Apr 2024
    07 Sep 2023 $0.0220 100.00% Final 11 Oct 2023
    08 Mar 2023 $0.0220 100.00% Interim 06 Apr 2023
    08 Sep 2022 $0.0220 100.00% Final 07 Oct 2022
    07 Mar 2022 $0.0220 100.00% Interim 04 Apr 2022
    09 Sep 2021 $0.0210 100.00% Final 08 Oct 2021
    09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
    05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
    05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
    06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
    08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
    06 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
    02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
    06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
    08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016

    MVF ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Monash IVF Group Ltd

    Monash IVF Group Ltd (ASX: MVF) is a specialist assisted reproductive services provider. The company offers fertility treatments and specialist diagnostic obstetric and gynaecological ultrasound services. Monash is among the leading providers of assisted reproductive services in Australia and Malaysia. It also has a cooperative agreement with a hospital in China. 

    MVF Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Jan 2026 $0.75 $0.00 0.00% 525,359 $0.75 $0.76 $0.74
    15 Jan 2026 $0.75 $-0.01 -1.32% 719,689 $0.76 $0.76 $0.75
    14 Jan 2026 $0.76 $0.01 1.34% 458,974 $0.76 $0.76 $0.75
    13 Jan 2026 $0.75 $-0.01 -1.33% 625,917 $0.76 $0.76 $0.74
    12 Jan 2026 $0.75 $0.00 0.00% 1,050,040 $0.76 $0.76 $0.74
    09 Jan 2026 $0.75 $0.00 0.00% 849,941 $0.76 $0.77 $0.74
    08 Jan 2026 $0.75 $0.00 0.00% 319,797 $0.75 $0.76 $0.74
    07 Jan 2026 $0.75 $-0.01 -1.32% 369,742 $0.76 $0.77 $0.75
    06 Jan 2026 $0.76 $0.01 1.33% 823,877 $0.75 $0.77 $0.74
    05 Jan 2026 $0.75 $0.00 0.00% 683,042 $0.75 $0.76 $0.74
    02 Jan 2026 $0.75 $0.02 2.72% 325,184 $0.73 $0.76 $0.73
    31 Dec 2025 $0.74 $-0.01 -1.35% 853,335 $0.75 $0.75 $0.73
    30 Dec 2025 $0.74 $0.01 1.37% 384,962 $0.74 $0.75 $0.73
    29 Dec 2025 $0.73 $-0.01 -1.36% 590,514 $0.72 $0.74 $0.72
    24 Dec 2025 $0.74 $-0.08 -9.76% 4,097,960 $0.70 $0.74 $0.69
    23 Dec 2025 $0.82 $0.01 1.23% 508,552 $0.82 $0.82 $0.82
    22 Dec 2025 $0.82 $0.00 0.00% 478,395 $0.82 $0.82 $0.82
    19 Dec 2025 $0.82 $0.00 0.00% 600,822 $0.82 $0.82 $0.82
    18 Dec 2025 $0.82 $-0.01 -1.22% 740,806 $0.82 $0.82 $0.82
    17 Dec 2025 $0.82 $0.01 1.23% 540,250 $0.82 $0.83 $0.82

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Dec 2025 Catherine (Cathy) Aston Sell 75,000 $53,928
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Zita Peach Non-Executive Director Oct 2016
    Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. She is a Non-executive Director of three private equity owned companies, Icon Group Pty Ltd, Vet Partners Pty Ltd and Nucleus Network Pty Ltd.
    Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
    Mr Davis worked for InvoCare for 20 years until 2008. For most of that time, he held the position of CEO and managed the growth of that business through several ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is member of Risk Committee.
    Dr Dwayne Crombie Non-Executive Director Nov 2025
    Mr Crombie has spent his entire career working in various parts of the healthcare system in both New Zealand and Australia. His experience has spanned public hospital provision, community-based, mental health and disability services. It has also included funding of public health and disability services, aged care, private health insurance and private healthcare. Dwayne originally trained in medicine and specialised in public health before moving on to senior management roles. He worked for global healthcare organisation Bupa for more than 15 years in several Managing Director roles. Dwaynes current governance roles include Southern Cross Healthcare and Southern Cross Society, as well as being chair of Repromed New Zealand, an IVF Provider.
    Mr Neil John Broekhuizen Non-Executive Director Jun 2014
    Mr Broekhuizen is the Joint Chief Executive Officer of Ironbridge. He has over 35 years of experience in the finance industry including 29 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. He is member of Risk Committee.
    Dr Richard Charles Henshaw Executive Director Apr 2014
    Dr Henshaw has practiced in the field of reproductive medicine since 1995. He worked as a Fertility Specialist for the Group and retired from clinical practice in August 2025. He has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
    Ms Catherine Jane West Non-Executive Director Sep 2020
    Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe.
    Ms Catherine (Cathy) Ann Aston Non-Executive Director Feb 2024
    Ms Aston is a Non executive Director/Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. She has commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. She is currently a Non-executive Director of Macquarie Investment Management Ltd (Chair of the Audit, Risk and Compliance committee), IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair). She is Chair of Risk Committee.
    Ms Victoria Atkinson Non-Executive Director Jan 2026
    --
    Mr Malik Jainudeen Chief Financial OfficerCompany Secretary Apr 2019
    -
    Johannes Lagerwij Asia Managing Director
    -
    Peggy North Chief Corporate Shared Services Officer
    -
    Malik Jainudeen Chief Financial OfficerCompany Secretary
    -
    Tedd Fuell Chief Governance and Risk Officer
    -
    Thierry Panthier Chief Information Officer
    -
    Rebecca Redden Chief Operating Officer
    -
    Deirdre Zander Fox Chief Scientific Officer
    -
    Luk Rombauts Group Medical Director
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson And Company Limited 37,767,969 9.69%
    Argo Investments Limited 28,381,705 7.28%
    Citicorp Nominees Pty Limited 27,642,111 7.09%
    J P Morgan Nominees Australia Pty Limited 27,637,494 7.09%
    HSBC Custody Nominees (Australia) Limited 21,532,960 5.53%
    HSBC Custody Nominees (Australia) Limited A/C 2 9,141,392 2.35%
    UBS Nominees Pty Ltd 4,642,413 1.19%
    BNP Paribas Nominees Pty Ltd 4,123,674 1.06%
    Masfen Securities Limited 4,000,000 1.03%
    J & P Chick Pty Limited 3,930,000 1.01%
    Creabird Pty Ltd 2,650,000 0.68%
    Neweconomy Com Au Nominees Pty Limited 2,637,466 0.68%
    BNP Paribas Nominees Pty Ltd i 2,584,913 0.66%
    Mr Troy Benjamin Ince & Mrs Nadine Julie Miller 2,250,000 0.58%
    Ippoliti Pty Ltd 2,011,336 0.52%
    Pacific Custodians Pty Limited 2,007,027 0.52%
    Netwealth Investments Limited 1,705,141 0.44%
    Mr Prashant Nadkarni 1,461,484 0.38%
    Gregg Property Holdings Pty Ltd 1,317,300 0.34%
    Mclachlan Future Fund Pty Ltd 1,300,000 0.32%

    Profile

    since

    Note